Anthracycline cardiotoxicity — prevention
- Limit cumulative anthracycline exposure when possible
- Baseline and serial LV function in at-risk patients
- Dexrazoxane reduces cardiotoxicity in selected patients
- Liposomal doxorubicin can lower cardiac exposure
- Control HTN and other CV risk
- New dysfunction → guideline-directed HF therapy
Use at a glance
- Limit cumulative anthracycline exposure when possible
Choosing treatment
- Liposomal doxorubicin can lower cardiac exposure
- New dysfunction → guideline-directed HF therapy
Practical pearls
- Baseline and serial LV function in at-risk patients
Treatment selection
- Dexrazoxane reduces cardiotoxicity in selected patients
- Control HTN and other CV risk
Self-check
- What treats new anthracycline-related cardiac dysfunction?
Guideline-directed HF therapy. - Which drug reduces anthracycline cardiotoxicity in selected patients?
Dexrazoxane.
Drugs used for this (1)
All clinical uses · Open Anthracycline cardiotoxicity — prevention in the interactive console ↗